The largest generic drugmaker in the world, Teva Pharmaceutical Industries, has reportedly posted a wonderful fourth quarter result with a rise in the net profit. The net profit is basically due to the acquisition of Barr and also the high sales of Copaxone, their treatment for multiple sclerosis.

It has been reported that this would be a very good year for the company and the major part of it is due to the new products that they had launched. It was an interesting fact that the profit for the fourth quarter had risen by almost 28 per cent in terms of revenue.

The net income was quoted at 94 cents for every share which is about $847 million when compared to what was $662 million or about 80 cents per share in the year 2008. Teva, which is basically based in Israel, is actually trying to reduce its dependency on its Copaxone as it is expected to face heady competition for the latest MS pills. It was an interesting fact that it had done well in and around the U. S. even though the sales of the treatment had lessened slightly after the price was increased by about 20 per cent.